Particle Therapy International Meeting - organised as part of LhARA initiative

Date: last week of Feb 2026 (Feb 27th or Feb 13th if possible to accommodate Marco Durante)

Venue: Institute of Physics (IOP) / hybrid

Sponsored by IOP - will need a badge/logo [contact/member: *Richard/Ken*]

IOP groups: Medical Physics; Biophysics; Particle Physics; Accelerators

Type of Meeting: One-day international hybrid-meeting

Time: 10am - 4pm

Sponsored by: Industry partners (e.g., Leo Cancer Care, additional sponsors to be determined –

RaySearch? CosyLab?) List approach. As all other groups £500

In kind: CNRS [contact: Ken]

EFOMP PT special interest group (SIG) – [SIG Chair: *Richard*]

IPEM - [member/contact: Richard]

PTCOG – [contact: *Richard*]
ARR – [contact: *Jason*]

AAPM PT Subcommittee (?) – [member/contact: *Richard*]

ESTRO (?) – [Contact: **Stuart/Pat**]

BIR - [Contact: **Stuart**]

Aim:

Establishment of an International Advisory Group to guide the biology, clinical applications, and development of particle therapy.

Background paper: Attached (?)

Target Audience:

Biologists, clinicians, and physicists interested in particle therapy, with a particular focus on heavy ions. UKRI-MRC/RTFC/EPSRC etc. DOHSC, DSRI. (*CRUK RadNet*)

Expected Outcome:

Publication on the current status and opportunities for LhARA: BIR(?) Business case for LhARA-for UKRI and DSRI and European applications

Organising Committee:

Pat Price, Ken Long, Richard A. Amos, Jason Parsons, Amato Giaccia, Matthew Williams, Stuart Green

Programme:

Session 1: Current Status and Technology – chaired by Ken Long

- Current Status of Particle Therapy Internationally: Clinical and Technological Where we
 will be in 10 years
 - Speaker: <u>Alejandro Mazel</u> / Tony Lomax / Niek Schreuder
- Main Challenges and Priority Areas for Development

- Barriers and solutions in production: Particle range, dose rate, spectral distribution,
 high LET, imaging techniques, end stations, detection of response
- o Speaker: Sandro Rossi and Katia Parodi and Harold Paganetti
- o Discussion: Ugo Amaldi

Session 2: Biological and Clinical Questions – chaired by Pat Price / Marco Durante

- Key Biological and Clinical Questions
 - o Lessons from FLASH therapy, spatially-fractionated, heavier-ions, etc.
 - Speakers: Yolanda Prezado + Joao Seco (both EFOMP PT SIG) + Jason Parsons + Kevin Price
- Immunological Evidence Supporting Different Mechanisms of Action
 - Stimulating interest from the immune-oncology community and pharmaceutical industry
 - Speakers: <u>Marco Durante</u> (PTCOG president)

Session 3: Clinical and Commercial Development – chaired by Richard Amos

- Democratizing Particle Therapy
 - Feasibility of integrating with current radiotherapy practices and potential for economic growth across countries
 - Speakers: Thomas Bortfeld (AAPM) / Konrad Nesteruk (AAPM / PTCOG)
- Technology Development
 - Learning from rapid advancements in photon beam delivery in the commercial sector-business case
 - o Speaker: Leo cancer care: Rock Mackie / Niek Schreuder

Session 4: Roadmap for International Development

• LhARA as an International Research Facility

Round table: Ken / organising committee + Manjit Dosanjh (has international RT/PT interest)

Suggested Invited Speakers:

- Marco Durante (Darmstadt, Germany & Naples, Italy)
- Alejandro Mazel
- Manjit Dosanjh
- Marcel Kenton
- Jürgen Debus (Heidelberg) Clinical trials: past and future
- Jeff (NIH)

- Yolanda Prezado (CIMUS, Santiago de Compostela, Spain)
- Kevin Price or Marco Borghesi (Belfast)
- Rock Mackie
- Andy Henderson

Invited Participants:

UK Clinicians:

- Adrian Crellin (NHS England)
- David Thomson (Christie Trials Clinician)
- Anthony Chalmers (Glasgow Biology Research)
- Maria Hawkins (UCL/UCLH)
- Paul Sanghera (Birmingham TBD)
- Eugen Hug (MedAustron Clinical Director, previously involved with NHS England training)
- Members of RadNet

Next Steps:

- Confirm date and venue
- Secure sponsorships
- Finalize speaker invitations
- Develop detailed agenda
- Establish publication plan for post-meeting outcomes

This document serves as a proposal for structuring the meeting and finalizing key elements. Feedback and refinements are welcome.